Advancing Solid Tumor Development Through a Biology-Led Approach

Breast and gynecologic, lung and gastrointestinal cancers together account for approximately two-thirds of newly diagnosed solid tumor cases worldwide.¹ They are also areas where significant unmet need remains across disease stages, tumor subtypes and patient populations.

Concentrating efforts in these areas allows BeOne to pursue multiple biological drivers and therapeutic approaches within each area, while building the scientific and clinical expertise needed to advance programs over time.

The approach begins with the biology of the disease. BeOne identifies relevant biological drivers and targets, then selects the most appropriate therapeutic modality for further investigation.

Rather than beginning with a promising technology and searching for a place to apply it, BeOne builds each program around the scientific and clinical problem it is intended to address.

Different modalities enable diverse treatment approaches. Small molecules can inhibit disease-driving proteins, while protein degraders are designed to eliminate them. Antibody-drug conjugates deliver therapeutic payloads to cancer cells expressing specific markers. Multispecific antibodies can engage more than one biological target or immune pathway.

This biology-led approach informs which targets BeOne prioritizes, how programs are designed and where resources are invested across the solid tumor pipeline.

Within each priority disease area, BeOne is advancing multiple targets, mechanisms and modalities. The most advanced solid tumor programs in BeOne’s pipeline are directed at GPC3, PRMT5, CEA, B7-H4 and CDK4. They each target different biological and clinical challenges, broadening the ways BeOne can investigate these cancers.

That range creates several development possibilities. Programs can advance independently, relevant targets can be pursued across more than one tumor type, and emerging assets can be evaluated with established treatments or one another where the science and evidence support it.

Together, these possibilities create a more versatile scientific foundation, one that can support development across patient populations, treatment settings and stages of disease while enabling proprietary combination strategies over time.

These programs represent one stage in a broader effort to build depth across BeOne’s priority disease areas. As new targets, modalities and programs continue to advance, BeOne will have more opportunities to address different patient populations, treatment settings and stages of disease.

Our broader ambition is to apply focused scientific investment, multiple complementary approaches and global development capabilities to create more options for patients and a stronger presence across solid tumor oncology.